Project Grant R01HL178726
Award Date
8/1/25
Completion Date
5/31/29
Dollars Obligated
$791K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Pensilvania, EE. UU.
Similar Awards
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $720,676 to the University of Pittsburgh to develop a novel nitro-fatty acid-based microbubble (NFAB) therapeutic strategy delivered via ultrasound-targeted microbubble cavitation (UTMC). The goal is to improve ventricular recovery and treat microvascular obstruction and myocardial fibrosis following myocardial infarction. The research aims...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $695,865.00 to the University of Pittsburgh to develop an optimized, minimally invasive strategy to treat ischemic cardiomyopathy (ICM). The key products and services to be delivered include: Evaluating the functional, geometric, and histopathologic effects of injecting three different thermoresponsive hydrogel formulations into an ICM...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) is funding the development and validation of a new Super-Resolution Intravascular Ultrasound (SR-IVUS) technology to enable high-resolution 3D imaging of the coronary vasa vasorum and thin fibrous cap of vulnerable atherosclerotic plaques. The $726,205 award, granted on April 22, 2025, supports the University of Pittsburgh's efforts to create a dual-mode SR-IVUS catheter...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $758,862 to Yale University to develop a multi-modality imaging approach for guiding the delivery of therapeutic hydrogels to the heart for prevention of remodeling after myocardial infarction (MI). The project aims to employ hybrid SPECT/CT imaging to non-invasively track markers of inflammation and fibroblast activation, and...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $767,077 to the University of North Carolina at Chapel Hill to validate and extend a platform technology for the delivery of protein-based drugs, with a focus on thrombolytic enzymes. The research aims to develop a biocompatible drug delivery system that can leverage the circulatory system as a natural drug depot, release the...
This Project Grant award of $108,030, provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), supports research to determine if neutrophils produced through emergency granulopoiesis, a reactive process that increases neutrophil production during immune challenges like myocardial infarction (MI), exhibit altered functions that contribute to the pathogenesis of heart failure after MI. The key objectives are 1) to assess...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under CFDA 93.837 - Cardiovascular Diseases Research provides $740,037 to the University of California, Los Angeles (UCLA) to investigate the role of cardiac fibroblasts in regulating angiogenesis and vascular formation following myocardial infarction. The research aims to evaluate the function of anti-angiogenic factors like collagen type XVIII expressed by cardiac fibroblasts, as well as determine if the...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), supports the development of a lesion-targeted nanotherapeutic to address vascular smooth muscle cell (VSMC) dysfunction and mitigate neointimal hyperplasia (NIH), which is a significant issue arising from vascular damage during interventions. The project aims to integrate in vitro transcribed CARMN RNA (a long non-coding RNA critical...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $549,665 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to the University of Maryland, Baltimore to conduct research on "Modulating the Resolution of Angiogenesis and Normalization of the Vasculature for Therapeutic Benefit." The goal is to advance the understanding of the fundamental processes that regulate the resolution of angiogenesis, in order to develop more effective therapeutic approaches for...
This $647,359 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports the engineering of biomaterials with controlled biomolecule delivery for cardiovascular applications. The key products and services to be delivered include: Efficient and sustainable delivery of microRNA-145 from a novel biomaterial (PVA-CDI immobilized aminated fucoidan, or PCAF) to smooth muscle cells to induce a contractile...